Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBITDA?
Shanghai Fosun Pharmaceutical (Group) CoSFOSF 77 EV-to-EBITDA is 15.86 as of Jul. 14, 2026, which is 17% below its 10-year median of 19.19. GuruFocus rates SFOSF with a GF Score™ of 77/100 and a GF Value™ of $2.47 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 739 Drug Manufacturers companies, Shanghai Fosun Pharmaceutical (Group) Co ranks worse than 57.37% on this metric.
SFOSF's EV-to-EBITDA is ranked worse than 57.37% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs SFOSF: 15.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Fosun Pharmaceutical (Group) Co's PE Ratio (TTM) for today is calculated as:
Shanghai Fosun Pharmaceutical (Group) Co's share price for today is $2.20.
Shanghai Fosun Pharmaceutical (Group) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.186.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBITDA Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBITDA vs Drug Manufacturers Industry
Shanghai Fosun Pharmaceutical (Group) Co's current Enterprise Value is $14,278 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $900 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a EV-to-EBITDA of 15.86 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Fosun Pharmaceutical (Group) Co. This is 17% below median its historical median of 19.19. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBITDA has ranged from 11.05 to 35.99. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #424 out of 739 companies in the Drug Manufacturers industry, placing it in the top 57.4%.
Is Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBITDA too high?
Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-EBITDA of 15.86 is 17% below median its 10-year median of 19.19. Over the past 10 years, this metric has ranged from a low of 11.05 to a high of 35.99. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Shanghai Fosun Pharmaceutical (Group) Co's value of 15.86 is 22.2% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #424 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #424 out of 739 companies for EV-to-EBITDA. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Shanghai Fosun Pharmaceutical (Group) Co's value of 15.86 is 22.2% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own EV-to-EBITDA has ranged from 11.05 to 35.99 over the past decade. While the company's 10-year median is 19.19 vs. the industry median of 12.98, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-EBITDA of 15.86 is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Fosun Pharmaceutical (Group) Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current EV-to-EBITDA is 15.86, which is 17% below median its own 10-year median of 19.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.47, compared to a current price of $2.20 — trading 10.9% below its estimated fair value. The current EV-to-EBITDA is 15.86, which is 17% below median its 10-year median of 19.19 and 22.2% above the Drug Manufacturers industry median of 12.98. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current EV-to-EBITDA is 15.86 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 10.9% below its estimated GF Value™ of $2.47.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
EV-to-EBITDA: 15.86 (17% below median its 10-year median of 19.19)
GF Value™: $2.47 vs. price of $2.20 (10.9% below fair value)
Industry Position: 22.2% above the Drug Manufacturers median (#424 of 739)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score
Get the complete analysis for SFOSF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
